The biopharmaceutical company said that the trial endpoints were the time to systemic disease progression and the change in velocity of Prostate Specific Antigen levels. Neither endpoint was achieved, prompting the company to cease further development of the compound in cancer. However, the biopharmaceutical company will continue to study the compound’s effect in Alzheimer’s disease.
The study showed that MPC-7869 was well tolerated over long-term administration in an elderly population, confirming the data from previous studies. Myriad said that the safety data gathered in the trial will be useful to ongoing trials of the drug in Alzheimer’s disease.